European Archives - Page 251 of 1449 - European Medical Journal

Controlling Asthma During Pregnancy: Key to Better Maternal and Infant Outcomes

Asthma affects nearly 1 in 10 pregnancies, and if left uncontrolled, it can lead to serious complications for both mother and baby. But with proper treatment and awareness of risk factors, many of these outcomes can be improved.

AI and Wearable Tech can Predict Diabetes Risk Before Symptoms

Discover how new AI can spot hidden diabetes risk earlier than ever before. Keep reading for the full story.

Pregabalin Raises Heart Failure Risk More Than Gabapentin in Older Adults

Discover the higher risk of heart failure with pregabalin versus gabapentin in older adults. Read the full study findings.

UKHSA Warns of Measles Surge Ahead of School Term

UK health officials urge parents to catch up on MMR vaccines as measles cases rise, warning of a possible surge when school resumes in September.

Daily Moisturising in Infants Shown to Reduce Eczema Risk

Daily moisturising may prevent infant eczema, even in low-risk babies, offering a practical approach for early skin care.

BMS’ Emma Charles on access, impact and inclusion

Emma shares her vision for healthcare, how AI is reshaping pharma and why access to innovation must be faster and fairer in Europe.

Expanding Treatment Horizons: Advancements in Key mCRC Populations

The following topics were covered during a symposium at the 2025 European Society for Medical Oncology Gastrointestinal Cancers (ESMO-GI)…

Does Early Cardiac Rehabilitation Improve Severe Acute Heart Failure?

Early cardiac rehabilitation did not improve function or rehospitalisation in severe heart failure, but mobility gains were seen.

Simon Lord, Associate Professor in Experimental Cancer Therapeutics, University of Oxford

Onc Now: Episode 23: From Lab to Life in Breast Cancer Care

How if scientific innovation transforming precision oncology? Simon Lord, Associate Professor in Experimental Cancer Therapeutics at the University of Oxford shares his expertise.

Treatment Advances for Muscle-Invasive Bladder Cancer

Despite aggressive interventions, the five-year survival rate remains below 50% for those with localised disease and plummets to less than 15% when metastasis occurs.